Download PDF
Semin Respir Crit Care Med 2012; 33(06): 588-594
DOI: 10.1055/s-0032-1325618
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Aspirin-Exacerbated Respiratory Disease: Update on Pathogenesis and Desensitization

Andrew A. White
1   Division of Allergy, Asthma, and Immunology, Scripps Clinic, San Diego, California
,
Donald D. Stevenson
1   Division of Allergy, Asthma, and Immunology, Scripps Clinic, San Diego, California
› Author Affiliations
Further Information

Publication History

Publication Date:
09 October 2012 (online)

    Permissions and Reprints

Abstract

Aspirin-exacerbated respiratory disease (AERD) is a unique syndrome of airway inflammation that frequently occurs in patients with nasal polyposis, chronic sinusitis, and asthma. These patients tend to have progressive and recalcitrant sinus disease requiring frequent surgical intervention and in many cases systemic corticosteroids. Much about the pathogenesis of AERD remains unclear, but environmental factors likely play a prominent role in its development. Avoidance of aspirin or nonsteroidal antiinflammatory drugs (NSAIDs) is imperative in the initial counseling of these patients. Because most of the exposure to these medications is available over the counter, most patients will experience a significant respiratory reaction to full therapeutic doses of seemingly innocent NSAIDs. Although the history of a reaction to aspirin or another NSAID is a very important part of making the diagnosis, the gold standard remains an observed aspirin challenge. Given the prevalence and usefulness of aspirin and NSAID therapy in primary care clinics, an accurate diagnosis should be made in all patients. Desensitization is an effective treatment option for many patients. Recent advances have made this procedure considerably safer and outpatient aspirin desensitization is now the standard of care.

Keywords

aspirin - nasal polyps - chronic sinusitis - asthma - nonsteroidal antiinflammatory drugs
 

  • References

  • 1 Hedman J, Kaprio J, Poussa T, Nieminen MM. Prevalence of asthma, aspirin intolerance, nasal polyposis and chronic obstructive pulmonary disease in a population-based study. Int J Epidemiol 1999; 28 (4) 717-722
    CrossrefPubMedGoogle Scholar
  • 2 Vally H, Taylor ML, Thompson PJ. The prevalence of aspirin intolerant asthma (AIA) in Australian asthmatic patients. Thorax 2002; 57 (7) 569-574
    CrossrefPubMedGoogle Scholar
  • 3 Kasper L, Sladek K, Duplaga M , et al. Prevalence of asthma with aspirin hypersensitivity in the adult population of Poland. Allergy 2003; 58 (10) 1064-1066
    CrossrefPubMedGoogle Scholar
  • 4 Gomes E, Cardoso MF, Praça F, Gomes L, Mariño E, Demoly P. Self-reported drug allergy in a general adult Portuguese population. Clin Exp Allergy 2004; 34 (10) 1597-1601
    CrossrefPubMedGoogle Scholar
  • 5 Jenkins C, Costello J, Hodge L. Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice. BMJ 2004; 328 (7437) 434-437
    CrossrefPubMedGoogle Scholar
  • 6 Kim JE, Kountakis SE. The prevalence of Samter's triad in patients undergoing functional endoscopic sinus surgery. Ear Nose Throat J 2007; 86 (7) 396-399
    PubMedGoogle Scholar
  • 7 Dursun AB, Woessner KA, Simon RA, Karasoy D, Stevenson DD. Predicting outcomes of oral aspirin challenges in patients with asthma, nasal polyps, and chronic sinusitis. Ann Allergy Asthma Immunol 2008; 100 (5) 420-425
    CrossrefPubMedGoogle Scholar
  • 8 Szczeklik A, Nizankowska E, Duplaga M ; AIANE Investigators. European Network on Aspirin-Induced Asthma. Natural history of aspirin-induced asthma. Eur Respir J 2000; 16 (3) 432-436
    CrossrefPubMedGoogle Scholar
  • 9 Lumry WR, Curd JG, Zeiger RS, Pleskow WW, Stevenson DD. Aspirin-sensitive rhinosinusitis: the clinical syndrome and effects of aspirin administration. J Allergy Clin Immunol 1983; 71 (6) 580-587
    CrossrefPubMedGoogle Scholar
  • 10 Pleskow WW, Stevenson DD, Mathison DA, Simon RA, Schatz M, Zeiger RS. Aspirin-sensitive rhinosinusitis/asthma: spectrum of adverse reactions to aspirin. J Allergy Clin Immunol 1983; 71 (6) 574-579
    CrossrefPubMedGoogle Scholar
  • 11 White AA, Ludington E, Mehra P, Stevenson DD, Simon RA. Effect of leukotriene modifier drugs on the safety of OACs. Ann Allergy Asthma Immunol 2006; 97 (5) 688-693
    CrossrefPubMedGoogle Scholar
  • 12 Chen AH, Bennett CR. Ketorolac-induced bronchospasm in an aspirin-intolerant patient. Anesth Prog 1994; 41 (4) 102-107
    PubMedGoogle Scholar
  • 13 Sitenga GL, Ing EB, Van Dellen RG, Younge BR, Leavitt JA. Asthma caused by topical application of ketorolac. Ophthalmology 1996; 103 (6) 890-892
    PubMedGoogle Scholar
  • 14 Settipane RA, Schrank PJ, Simon RA, Mathison DA, Christiansen SC, Stevenson DD. Prevalence of cross-sensitivity with acetaminophen in aspirin-sensitive asthmatic subjects. J Allergy Clin Immunol 1995; 96 (4) 480-485
    CrossrefPubMedGoogle Scholar
  • 15 Gyllfors P, Bochenek G, Overholt J , et al. Biochemical and clinical evidence that aspirin-intolerant asthmatic subjects tolerate the cyclooxygenase 2-selective analgetic drug celecoxib. J Allergy Clin Immunol 2003; 111 (5) 1116-1121
    CrossrefPubMedGoogle Scholar
  • 16 Woessner K, Simon RA, Stevenson DD. The safety of celecoxib in aspirin exacerbated respiratory disease. Arthritis Rheum 2002; 46 (8) 2201-2206
    CrossrefPubMedGoogle Scholar
  • 17 Stevenson DD, Simon RA. Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma. J Allergy Clin Immunol 2001; 108 (1) 47-51
    CrossrefPubMedGoogle Scholar
  • 18 Bavbek S, Dursun AB, Dursun E, Eryilmaz A, Misirligil Z. Safety of meloxicam in aspirin-hypersensitive patients with asthma and/or nasal polyps. A challenge-proven study. Int Arch Allergy Immunol 2007; 142 (1) 64-69
    CrossrefPubMedGoogle Scholar
  • 19 Chang JE, Ding D, White AA, Martin J, Stevenson DD. Smoking, environmental tobacco smoke, and aspirin exacerbated respiratory disease [abstract]. J Allergy Clin Immunol 2011; 127: AB135
    PubMedGoogle Scholar
  • 20 Jafek BW, Smith CM, Moran DT, Johnson EW, Eller PM. Effects on the upper respiratory passages. Otolaryngol Head Neck Surg 1992; 106 (6) 720-729
    PubMedGoogle Scholar
  • 21 Bascom R, Kesavanathan J, Fitzgerald TK, Cheng KH, Swift DL. Sidestream tobacco smoke exposure acutely alters human nasal mucociliary clearance. Environ Health Perspect 1995; 103 (11) 1026-1030
    CrossrefPubMedGoogle Scholar
  • 22 Tamashiro E, Xiong G, Anselmo-Lima WT, Kreindler JL, Palmer JN, Cohen NA. Cigarette smoke exposure impairs respiratory epithelial ciliogenesis. Am J Rhinol Allergy 2009; 23 (2) 117-122
    CrossrefPubMedGoogle Scholar
  • 23 Rusznak C, Sapsford RJ, Devalia JL , et al. Cigarette smoke potentiates house dust mite allergen-induced increase in the permeability of human bronchial epithelial cells in vitro. Am J Respir Cell Mol Biol 1999; 20 (6) 1238-1250
    CrossrefPubMedGoogle Scholar
  • 24 Ronchetti R, Macri F, Ciofetta G , et al. Increased serum IgE and increased prevalence of eosinophilia in 9-year-old children of smoking parents. J Allergy Clin Immunol 1990; 86 (3 Pt 1) 400-407
    CrossrefPubMedGoogle Scholar
  • 25 Taylor RG, Gross E, Joyce H, Holland F, Pride NB. Smoking, allergy, and the differential white blood cell count. Thorax 1985; 40 (1) 17-22
    CrossrefPubMedGoogle Scholar
  • 26 Eddleston J, Lee RU, Doerner AM, Herschbach J, Zuraw BL. Cigarette smoke decreases innate responses of epithelial cells to rhinovirus infection. Am J Respir Cell Mol Biol 2011; 44 (1) 118-126
    CrossrefPubMedGoogle Scholar
  • 27 Davoine F, Cao M, Wu Y , et al. Virus-induced eosinophil mediator release requires antigen-presenting and CD4+ T cells. J Allergy Clin Immunol 2008; 122 (1) 69-77 , 77, e1–e2
    CrossrefPubMedGoogle Scholar
  • 28 Huang YJ, Nelson CE, Brodie EL , et al; National Heart, Lung, and Blood Institute's Asthma Clinical Research Network. Airway microbiota and bronchial hyperresponsiveness in patients with suboptimally controlled asthma. J Allergy Clin Immunol 2011; 127 (2) 372-381 , e1–e3
    CrossrefPubMedGoogle Scholar
  • 29 Samter M, Beers Jr RF. Intolerance to aspirin: clinical studies and consideration of its pathogenesis. Ann Intern Med 1968; 68 (5) 975-983
    CrossrefPubMedGoogle Scholar
  • 30 Szczeklik A, Stevenson DD. Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management. J Allergy Clin Immunol 2003; 111 (5) 913-921 , quiz 922
    CrossrefPubMedGoogle Scholar
  • 31 Sestini P, Armetti L, Gambaro G , et al. Inhaled PGE2 prevents aspirin-induced bronchoconstriction and urinary LTE4 excretion in aspirin-sensitive asthma. Am J Respir Crit Care Med 1996; 153 (2) 572-575
    CrossrefPubMedGoogle Scholar
  • 32 Christie PE, Tagari P, Ford-Hutchinson AW , et al. Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. Am Rev Respir Dis 1991; 143 (5 Pt 1) 1025-1029
    CrossrefPubMedGoogle Scholar
  • 33 Daffern PJ, Muilenburg D, Hugli TE, Stevenson DD. Association of urinary leukotriene E4 excretion during aspirin challenges with severity of respiratory responses. J Allergy Clin Immunol 1999; 104 (3 Pt 1) 559-564
    CrossrefPubMedGoogle Scholar
  • 34 Stevenson DD, Szczeklik A. Clinical and pathologic perspectives on aspirin sensitivity and asthma. J Allergy Clin Immunol 2006; 118 (4) 773-786 , quiz 787–788
    CrossrefPubMedGoogle Scholar
  • 35 Sousa AR, Parikh A, Scadding G, Corrigan CJ, Lee TH. Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis. N Engl J Med 2002; 347 (19) 1493-1499
    CrossrefPubMedGoogle Scholar
  • 36 Berges-Gimeno MP, Simon RA, Stevenson DD. Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2003; 111 (1) 180-186
    CrossrefPubMedGoogle Scholar
  • 37 Berges-Gimeno MP, Simon RA, Stevenson DD. Early effects of aspirin desensitization treatment in asthmatic patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2003; 90 (3) 338-341
    CrossrefPubMedGoogle Scholar
  • 38 Lee JY, Simon RA, Stevenson DD. Selection of aspirin dosages for aspirin desensitization treatment in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2007; 119 (1) 157-164
    CrossrefPubMedGoogle Scholar
  • 39 Rozsasi APD, Polzehl D, Deutschle T , et al. Long-term treatment with aspirin desensitization: a prospective clinical trial comparing 100 and 300 mg aspirin daily. Allergy 2008; 63 (9) 1228-1234
    CrossrefPubMedGoogle Scholar
  • 40 Pleskow WW, Stevenson DD, Mathison DA, Simon RA, Schatz M, Zeiger RS. Aspirin desensitization in aspirin-sensitive asthmatic patients: clinical manifestations and characterization of the refractory period. J Allergy Clin Immunol 1982; 69 (1 Pt 1) 11-19
    PubMedGoogle Scholar
  • 41 Stevenson DD, Simon RA. Selection of patients for aspirin desensitization treatment. J Allergy Clin Immunol 2006; 118 (4) 801-804
    CrossrefPubMedGoogle Scholar
  • 42 Katial RK, Strand M, Prasertsuntarasai T, Leung R, Zheng W, Alam R. The effect of aspirin desensitization on novel biomarkers in aspirin-exacerbated respiratory diseases. J Allergy Clin Immunol 2010; 126 (4) 738-744
    CrossrefPubMedGoogle Scholar
  • 43 Borish L, Rosenwasser LJ. Cytokines in allergic inflammation. In: Adkinson NJ, Busse WW, Bochner BS, Holgate ST, Lemanske RF, Simons FER, , eds. Middleton: Allergy Principles and Practice. 7th ed. Philadelphia, PA: Elsevier; 2009: 165-179
    CrossrefGoogle Scholar
  • 44 Steinke JW, Culp JA, Kropf E, Borish L. Modulation by aspirin of nuclear phospho-signal transducer and activator of transcription 6 expression: possible role in therapeutic benefit associated with aspirin desensitization. J Allergy Clin Immunol 2009; 124 (4) 724-730 , e4
    CrossrefPubMedGoogle Scholar
  • 45 Cianferoni A, Schroeder JT, Kim J , et al. Selective inhibition of interleukin-4 gene expression in human T cells by aspirin. Blood 2001; 97 (6) 1742-1749
    CrossrefPubMedGoogle Scholar
  • 46 Perez-G M, Melo M, Keegan AD, Zamorano J. Aspirin and salicylates inhibit the IL-4- and IL-13-induced activation of STAT6. J Immunol 2002; 168 (3) 1428-1434
    PubMedGoogle Scholar
  • 47 Juergens UR, Christiansen SC, Stevenson DD, Zuraw BL. Inhibition of monocyte leukotriene B4 production after aspirin desensitization. J Allergy Clin Immunol 1995; 96 (2) 148-156
    CrossrefPubMedGoogle Scholar
  • 48 Arm JP, O'Hickey SP, Spur BW, Lee TH. Airway responsiveness to histamine and leukotriene E4 in subjects with aspirin-induced asthma. Am Rev Respir Dis 1989; 140 (1) 148-153
    CrossrefPubMedGoogle Scholar
  • 49 Sanak M, Szczeklik A. Leukotriene C4 synthase polymorphism and aspirin-induced asthma. J Allergy Clin Immunol 2001; 107: 561-562
    PubMedGoogle Scholar
  • 50 Dahlén SE, Malmström K, Nizankowska E , et al. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165 (1) 9-14
    CrossrefPubMedGoogle Scholar
  • 51 White AA, Stevenson DD, Simon RA. The blocking effect of essential controller medications during aspirin challenges in patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2005; 95 (4) 330-335
    CrossrefPubMedGoogle Scholar
  • 52 White AA, Bigby TA, Stevenson DD. Intranasal ketorolac challenge for the diagnosis of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2006; 97 (2) 190-195
    CrossrefPubMedGoogle Scholar
  • 53 Lee RU, White AA, Ding D , et al. Use of intranasal ketorolac and modified oral aspirin challenge for desensitization of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2010; 105 (2) 130-135
    CrossrefPubMedGoogle Scholar